TG Therapeutics Files 2025 DEF 14A
Ticker: TGTX · Form: DEF 14A · Filed: Apr 30, 2025 · CIK: 1001316
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
Related Tickers: TGTX
TL;DR
TG Therapeutics filed its annual proxy statement (DEF 14A) detailing exec pay and corporate governance.
AI Summary
TG Therapeutics, Inc. filed its DEF 14A on April 30, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and other corporate governance matters. The company's principal executive offices are located at 2 Gansevoort Street, 9th Floor, New York, NY 10014.
Why It Matters
This filing provides crucial insights into the compensation of TG Therapeutics' top executives and the company's governance structure, which can influence investor decisions.
Risk Assessment
Risk Level: low — This is a routine annual filing (DEF 14A) that primarily concerns corporate governance and executive compensation, not immediate operational or financial risks.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for the filing)
- 20250430 — Filing Date (Date the DEF 14A was submitted to the SEC)
Key Players & Entities
- TG THERAPEUTICS, INC. (company) — Filer
- 2 GANSEVOORT STREET, 9TH FLOOR (location) — Business Address
- NEW YORK (location) — Business Address City
- 10014 (location) — Business Address Zip
- MANHATTAN PHARMACEUTICALS INC (company) — Former Company Name
- ATLANTIC TECHNOLOGY VENTURES INC (company) — Former Company Name
- ATLANTIC PHARMACEUTICALS INC (company) — Former Company Name
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is filed by a company to solicit proxies from its shareholders for an upcoming annual or special meeting of shareholders. It contains detailed information about matters to be voted on, including executive compensation, director elections, and other corporate governance issues.
What is the fiscal year end for TG Therapeutics, Inc. as indicated in this filing?
The fiscal year end for TG Therapeutics, Inc. is December 31, as stated in the filing details.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 30, 2025.
What is the business address of TG Therapeutics, Inc.?
The business address of TG Therapeutics, Inc. is 2 Gansevoort Street, 9th Floor, New York, NY 10014.
Has TG Therapeutics, Inc. operated under previous names?
Yes, TG Therapeutics, Inc. has operated under previous names including Manhattan Pharmaceuticals Inc, Atlantic Technology Ventures Inc, and Atlantic Pharmaceuticals Inc.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 30, 2025 regarding TG THERAPEUTICS, INC. (TGTX).